Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ZIMMER BIOMET HOLDINGS, INC. reported revenue of $8.23B, up 7.2% year over year. Operating margin was 13.3% and net margin 8.6%, on a free-cash-flow margin of 17.9% with capital expenditure at 2.7% of revenue. Every figure is computed directly from ZBH's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $8.23B | 13.3% | 8.6% |
| FY2024 | $7.68B | 16.7% | 11.8% |
| FY2023 | $7.39B | 17.3% | 13.8% |
| FY2022 | $6.94B | 10.0% | 3.3% |
| FY2021 | $6.83B | 12.6% | 5.9% |
How does ZBH compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.